

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

SENATE BILL 100

**52ND LEGISLATURE - STATE OF NEW MEXICO - SECOND SESSION, 2016**

INTRODUCED BY

William P. Soules

AN ACT

RELATING TO OPIOID OVERDOSE; REQUIRING HEALTH CARE PROVIDERS WHO PRESCRIBE, DISTRIBUTE OR DISPENSE OPIOIDS TO BE TRAINED ON THE USE OF NALOXONE; REQUIRING THE COUNSELING OF PATIENTS ON THE RISKS OF OVERDOSE AND ABOUT OPIOID OVERDOSE REVERSAL MEDICATION; REQUIRING PHARMACISTS AND PHARMACIST CLINICIANS WHO PRESCRIBE OPIOIDS UNDER A WRITTEN PROTOCOL TO BE TRAINED ON THE USE OF NALOXONE; RELEASING CERTAIN PERSONS FROM CIVIL LIABILITY OR CRIMINAL PROSECUTION FOR ADMINISTERING, PRESCRIBING, DISPENSING OR DISTRIBUTING, DIRECTLY OR INDIRECTLY, AN OPIOID ANTAGONIST; AUTHORIZING NON-PATIENT-SPECIFIC STANDING ORDERS TO DISPENSE NALOXONE; AMENDING, REPEALING AND ENACTING SECTIONS OF THE NMSA 1978.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

**SECTION 1.** Section 24-2D-2 NMSA 1978 (being Laws 1999,

.203113.2

underscoring material = new  
~~[bracketed material] = delete~~

underscoring material = new  
~~[bracketed material] = delete~~

1 Chapter 126, Section 2, as amended) is amended to read:

2 "24-2D-2. DEFINITIONS.--As used in the Pain Relief Act:

3 A. "accepted guideline" means the most current  
4 clinical pain management guideline developed by the American  
5 geriatrics society or the American pain society or a clinical  
6 pain management guideline based on evidence and expert opinion  
7 that has been accepted by the New Mexico medical board;

8 B. "acute pain" means the normal, predicted  
9 physiological response to a noxious chemical or thermal or  
10 mechanical stimulus, typically associated with invasive  
11 procedures, trauma or disease and generally time-limited;

12 C. "board" means the licensing board of a health  
13 care provider;

14 D. "chronic pain" means pain that persists after  
15 reasonable medical efforts have been made to relieve the pain  
16 or its cause and that continues, either continuously or  
17 episodically, for longer than three consecutive months.

18 "Chronic pain" does not include pain associated with a terminal  
19 condition or with a progressive disease that, in the normal  
20 course of progression, may reasonably be expected to result in  
21 a terminal condition;

22 E. "clinical expert" means a person who by reason  
23 of specialized education or substantial relevant experience in  
24 pain management has knowledge regarding current standards,  
25 practices and guidelines;

.203113.2

underscored material = new  
[bracketed material] = delete

1 F. "disciplinary action" means any formal action  
2 taken by a board against a health care provider, upon a finding  
3 of probable cause that the health care provider has engaged in  
4 conduct that violates the board's practice act;

5 G. "health care provider" means a person who is  
6 licensed or otherwise authorized by law to provide health care  
7 in the ordinary course of business or practice of the person's  
8 profession and who has prescriptive authority within the limits  
9 of the person's license;

10 H. "opioid analgesic" means buprenorphine,  
11 butorphanol, codeine, hydrocodone, hydromorphone, levorphanol,  
12 mepiridine, methadone, morphine, nalbuphine, oxycodone,  
13 oxymorphone, pentazocine and propoxyphene as well as their  
14 brand names, isomers and combinations;

15 I. "opioid antagonist" means a drug approved by the  
16 federal food and drug administration that when administered  
17 negates or neutralizes in whole or in part the pharmacological  
18 effects of an opioid analgesic in the body, including naloxone  
19 and such other medications approved by the board of pharmacy  
20 for the reversal of opioid analgesic overdoses;

21 [~~H.~~] J. "pain" means acute and chronic pain; and

22 [~~I.~~] K. "therapeutic purpose" means the use of  
23 pharmaceutical and non-pharmaceutical medical treatment that  
24 conforms substantially to accepted guidelines for pain  
25 management."

.203113.2

underscored material = new  
[bracketed material] = delete

1           SECTION 2. A new section of the Pain Relief Act is  
2 enacted to read:

3           "[NEW MATERIAL] REQUIREMENTS FOR HEALTH CARE PROVIDERS WHO  
4 PRESCRIBE, DISTRIBUTE OR DISPENSE OPIOID ANALGESICS.--

5           A. Effective January 1, 2017, no health care  
6 provider shall prescribe, distribute or dispense an opioid  
7 analgesic unless such person has completed opioid overdose  
8 prevention training on the use of naloxone.

9           B. The board responsible for regulatory oversight  
10 of each category of health care provider who is licensed or  
11 otherwise authorized to prescribe, distribute or dispense  
12 opioid analgesics shall promulgate rules regarding the opioid  
13 overdose prevention training required in Subsection A of this  
14 section, allow such training to be completed online and make  
15 such training available at no cost to such health care  
16 providers.

17           C. A health care provider who prescribes,  
18 distributes or dispenses an opioid analgesic for the first time  
19 to a patient shall counsel the patient on the risks of overdose  
20 and inform the patient of the availability of an opioid  
21 antagonist. With respect to a patient to whom an opioid  
22 analgesic has previously been prescribed, distributed or  
23 dispensed by the health care provider, the health care provider  
24 shall counsel the patient on the risks of overdose and inform  
25 the patient of the availability of an opioid antagonist on the

.203113.2

underscored material = new  
[bracketed material] = delete

1 first occasion that the health care provider prescribes,  
2 distributes or dispenses an opioid analgesic each calendar  
3 year.

4 D. A health care provider who prescribes an opioid  
5 analgesic for a patient shall offer the patient a prescription  
6 for naloxone, within the scope of the health care provider's  
7 authorized practice, unless otherwise indicated in the  
8 professional judgment of the health care provider."

9 SECTION 3. A new section of the Pain Relief Act is  
10 enacted to read:

11 "[NEW MATERIAL] REQUIREMENTS FOR PRESCRIBING PURSUANT TO  
12 WRITTEN PROTOCOL OR DISPENSING OPIOID ANALGESICS BY PERSONS  
13 REGULATED BY THE BOARD OF PHARMACY.--

14 A. Effective January 1, 2017, a person licensed or  
15 otherwise authorized by the board of pharmacy to prescribe  
16 pursuant to written protocol or dispense an opioid analgesic  
17 shall not prescribe or dispense an opioid analgesic unless such  
18 person has completed opioid overdose prevention training on the  
19 use of naloxone.

20 B. The board of pharmacy shall promulgate rules  
21 regarding the opioid overdose prevention training required in  
22 Subsection A of this section, allow such training to be  
23 completed online and make such training available at no cost to  
24 its licensees."

25 SECTION 4. A new section of the Pain Relief Act is

.203113.2

underscored material = new  
[bracketed material] = delete

1 enacted to read:

2 "[NEW MATERIAL] RELEASE FROM LIABILITY.--

3 A. A person licensed or otherwise authorized to  
4 prescribe, distribute or dispense an opioid antagonist shall  
5 not be subject to civil liability or criminal prosecution for  
6 prescribing, dispensing or distributing, directly or  
7 indirectly, an opioid antagonist to a person at risk of  
8 experiencing an opioid-related overdose, or to a family member,  
9 friend or other person in a position to assist a person  
10 experiencing, or at risk of experiencing, an opioid-related  
11 overdose.

12 B. A person who comes to the aid or rescue of  
13 another person may administer an opioid antagonist to that  
14 other person if the rescuer:

15 (1) in good faith, believes the other person  
16 is experiencing a drug overdose; and

17 (2) acts with reasonable care in administering  
18 the drug to the other person.

19 C. A person who administers an opioid antagonist to  
20 another person pursuant to Subsection B of this section shall  
21 not be subject to civil liability or criminal prosecution as a  
22 result of the administration of the drug."

23 SECTION 5. A new section of the Pain Relief Act is  
24 enacted to read:

25 "[NEW MATERIAL] NON-PATIENT-SPECIFIC STANDING ORDERS TO

.203113.2

underscoring material = new  
~~[bracketed material] = delete~~

1 DISPENSE NALOXONE.--

2 A. The secretary of health shall direct the medical  
3 director of the department of health to initiate non-patient-  
4 specific standing orders to dispense naloxone with a sufficient  
5 number of retail pharmacies to ensure that the public  
6 throughout the state has access to opioid antagonists on  
7 weekdays, after hours and on weekends.

8 B. The medical director of a hospital or a health  
9 plan may initiate non-patient-specific standing orders to  
10 dispense naloxone to one or more retail pharmacies to ensure  
11 that the public has access to opioid antagonists throughout the  
12 state on weekdays, after hours and on weekends. For purposes  
13 of this subsection, "health plan" means a health maintenance  
14 organization, provider service network or third-party payer or  
15 its agent."

16 SECTION 6. REPEAL.--Sections 24-23-1 and 24-23-2 NMSA  
17 1978 (being Laws 2001, Chapter 228, Sections 1 and 2) are  
18 repealed.